Advertisement
CLPT vs LUNG
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLPT is a Buy and LUNG is a Hold.
CLPT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CLPT turned positive on October 26, 2026. Looking at past instances where CLPT's MACD turned positive, the stock continued to rise in 47 of 54 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLPT's RSI Indicator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CLPT as a result. In 78 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +10.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 217 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 58 cases where CLPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
CLPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CLPT moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CLPT broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLPT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (28.166) is slightly higher than the industry average of (4.204). P/E Ratio (-8.432) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
LUNG in upward trend: 10-day moving average moved above 50-day moving average on October 29, 2026
The 10-day moving average for LUNG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 67 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for LUNG just turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +59.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 215 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for LUNG moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 29 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.827) is normal, around the industry mean (4.204). P/E Ratio (-2.243) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CLPT | LUNG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 44 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 77 | 34 | |
P/E GROWTH RATING 1..100 | 15 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 2 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LUNG's Valuation (30) in the null industry is in the same range as CLPT (47). This means that LUNG’s stock grew similarly to CLPT’s over the last 12 months.
LUNG's Profit vs Risk Rating (100) in the null industry is in the same range as CLPT (100). This means that LUNG’s stock grew similarly to CLPT’s over the last 12 months.
LUNG's SMR Rating (98) in the null industry is in the same range as CLPT (100). This means that LUNG’s stock grew similarly to CLPT’s over the last 12 months.
LUNG's Price Growth Rating (34) in the null industry is somewhat better than the same rating for CLPT (77). This means that LUNG’s stock grew somewhat faster than CLPT’s over the last 12 months.
CLPT's P/E Growth Rating (15) in the null industry is significantly better than the same rating for LUNG (97). This means that CLPT’s stock grew significantly faster than LUNG’s over the last 12 months.
| CLPT | LUNG | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 77% |
| Advances ODDS (%) | 6 days ago 79% | 6 days ago 81% |
| Declines ODDS (%) | 2 days ago 87% | 2 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 78% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLPT’s FA Score shows that 1 FA rating(s) are green while LUNG’s FA Score has 1 green FA rating(s).
- CLPT’s FA Score: 1 green, 4 red.
- LUNG’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLPT’s TA Score shows that 4 TA indicator(s) are bullish while LUNG’s TA Score has 5 bullish TA indicator(s).
- CLPT’s TA Score: 4 bullish, 6 bearish.
- LUNG’s TA Score: 5 bullish, 5 bearish.
Price Growth
CLPT (@Medical/Nursing Services) experienced а +10.07% price change this week, while LUNG (@Medical/Nursing Services) price change was +32.31% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.28%. For the same industry, the average monthly price growth was -5.93%, and the average quarterly price growth was -7.92%.
Reported Earning Dates
CLPT is expected to report earnings on Mar 03, 2027.
LUNG is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Medical/Nursing Services (+0.28% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
CLPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | -6.75% | ||
| ICUI - CLPT | 57% Loosely correlated | -0.85% | ||
| ISRG - CLPT | 46% Loosely correlated | +1.12% | ||
| A - CLPT | 45% Loosely correlated | -1.65% | ||
| NVST - CLPT | 45% Loosely correlated | +5.10% | ||
| SMTI - CLPT | 43% Loosely correlated | -2.31% | ||
More | ||||
LUNG and
Correlation & Price change
A.I.dvisor indicates that over the last year, LUNG has been loosely correlated with SRTS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if LUNG jumps, then SRTS could also see price increases.
| Ticker / NAME | Correlation To LUNG | 1D Price Change % | ||
|---|---|---|---|---|
| LUNG | 100% | -14.14% | ||
| SRTS - LUNG | 57% Loosely correlated | -0.36% | ||
| BAX - LUNG | 53% Loosely correlated | +5.30% | ||
| ALGN - LUNG | 52% Loosely correlated | +2.83% | ||
| UTMD - LUNG | 32% Poorly correlated | +3.64% | ||
| CLPT - LUNG | 30% Poorly correlated | -6.75% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AVIV | 79.39 | 0.11 | +0.14% |
| Avantis International Large Cap Value ETF (AVIV) | |||
| CEMB | 43.93 | -0.19 | -0.43% |
| iShares J.P. Morgan EM Corporate Bond ETF (CEMB) | |||
| XISE | 30.16 | -0.16 | -0.53% |
| FT Vest U.S. Equity Buffer & Premium Income ETF - September (XISE) | |||
| CATG | 5.71 | -0.16 | -2.73% |
| Leverage Shares 2X Long CAT Daily ETF (CATG) | |||
| GNOM | 66.83 | -2.78 | -4.00% |
| Global X Genomics & Biotechnology ETF (GNOM) | |||